Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Terry D. who wrote (2996)	4/5/1999 10:30:00 AM
From: Alys Hall	Read Replies (1) \| Respond to of 3702

Where is Rubenstein and when will TCLN ever get the kind of coverage that Sugen did? With the story in Chicago and the great work that's being done what is our problem? I copied this from Tom Calandra's column for posting while wondering why Rubenstein couldn't get something like this done: -- Does "60 Minutes" rank in the stock market? We'll see Monday, after the CBS television show aired a generally positive report on a cancer drug in development by Sugen (SUGN), a California biotechnology company. Sugen shares, though weak in early trading on the Nasdaq, saw a roughly seven-point rise to 22 1/2 in the 10-day run-up to the Sunday "60 Minutes" segment. The company's SU5416 is getting treatment at the University of California Los Angeles, which has started trials of the Sugen on people with advanced colon cancer. See the original column..